Basilea PharmaceuticaXSWX:BSLN -0.57%62 Quick Ratio is 4.68 as of Dec. 2025, which is 34% above its 10-year median of 3.49. GuruFocus rates XSWX:BSLN with a GF Score™ of 62/100 and a GF Value™ of CHF57.38 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Basilea Pharmaceutica ranks better than 56.97% on this metric.
Basilea Pharmaceutica has a quick ratio of 4.68. It generally indicates good short-term financial strength.
The historical rank and industry rank for Basilea Pharmaceutica's Quick Ratio or its related term are showing as below:
XSWX:BSLN'
s Quick Ratio Range Over the Past 10 Years
Min: 1.25 Med: 3.49 Max: 4.68
Current: 4.68
During the past 13 years, Basilea Pharmaceutica's highest Quick Ratio was 4.68. The lowest was 1.25. And the median was 3.49.
XSWX:BSLN's Quick Ratio is ranked better than 56.97% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs XSWX:BSLN: 4.68
Basilea Pharmaceutica (XSWX:BSLN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Basilea Pharmaceutica Quick Ratio Related Terms
Basilea Pharmaceutica Quick Ratio Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Basilea Pharmaceutica's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Quick Ratio of 4.68 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Basilea Pharmaceutica and its competitors. This is 34% above median its historical median of 3.49. Over the past decade, Basilea Pharmaceutica's Quick Ratio has ranged from 1.25 to 4.68. According to the industry distribution chart, Basilea Pharmaceutica ranks #608 out of 1413 companies in the Biotechnology industry, placing it in the top 43%.
Is Basilea Pharmaceutica's Quick Ratio too high?
Basilea Pharmaceutica's current Quick Ratio of 4.68 is 34% above median its 10-year median of 3.49. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 4.68. The Biotechnology industry median Quick Ratio is 3.60. Basilea Pharmaceutica's value of 4.68 is 30% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #608 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #608 out of 1413 companies for Quick Ratio. This puts Basilea Pharmaceutica in the upper half of its industry. The industry median Quick Ratio is 3.60. Basilea Pharmaceutica's value of 4.68 is 30% above this benchmark. Historically, Basilea Pharmaceutica's own Quick Ratio has ranged from 1.25 to 4.68 over the past decade. While the company's 10-year median is 3.49 vs. the industry median of 3.60, Basilea Pharmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Quick Ratio of 4.68 is 30% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Quick Ratio is 4.68, which is 34% above median its own 10-year median of 3.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF51.90 — trading 9.6% below its estimated fair value. The current Quick Ratio is 4.68, which is 34% above median its 10-year median of 3.49 and 30% above the Biotechnology industry median of 3.60. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Quick Ratio is 4.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Quick Ratio: 4.68 (34% above median its 10-year median of 3.49)
GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
Industry Position: 30% above the Biotechnology median (#608 of 1413)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
